Latest Advances in Lung Cancer Research

Recent studies confirm genomic testing for NSCLC enhances treatment choices and survival, advocating for its standardization in clinical practice.

A novel nanoparticle vaccine halts lung cancer spread in mice by training the immune system to attack tumor cells, showing promise for post-surgery cancer prevention.

UCLA researchers received a $6 million grant to refine a liquid biopsy blood test for early, accurate lung cancer detection and treatment guidance.

Researchers developed a test detecting proteins in blood that indicate lung cancer spread, promising for early metastasis detection and treatment guidance.

Johnson & Johnson’s Rybrevant shows comparable efficacy to AstraZeneca’s Tagrisso in advanced NSCLC, suggesting potential as an initial treatment option.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

This study assessed real-world survival among older patients with non–small-cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy only.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.

Early onset of menstruation and menopause may increase women’s lung cancer risk, suggesting a possible hormonal influence; further research is needed.

Fred Hutchinson Cancer Center received a $30 million NCI grant to enhance cancer research and support vital services for the next five years.

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.